Test Price
650 AED✅ Home Collection Available
Goodpasture's Syndrome Panel in UAE | 650 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited dual-method processing combining ELISA with indirect immunofluorescence confirmation.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Temperature-monitored transport ensures specimen integrity from draw to analysis.
Clinical Guidance: Telephonic post-test result interpretation by DHA-licensed specialist physicians to support urgent clinical decision-making for anti-GBM disease management.
Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731 for eligible insurance plans.
Test Overview & Methodology
The Goodpasture's Syndrome Panel is a serological diagnostic assay that detects circulating anti-glomerular basement membrane (anti-GBM) antibodies, predominantly immunoglobulin G (IgG). This test is indicated for patients presenting with rapidly progressive glomerulonephritis and pulmonary hemorrhage to confirm anti-GBM disease, a life-threatening autoimmune disorder. The panel employs a dual-method approach combining enzyme-linked immunosorbent assay (ELISA) for quantitative screening with indirect immunofluorescence (IFA) for confirmatory visualization, providing the highest available diagnostic reliability.
| Feature | DNA Labs UAE Goodpasture's Panel | Closest Alternative (Routine Labs) |
|---|---|---|
| Methodology | Enzyme Immunoassay (ELISA) with Indirect Immunofluorescence (IFA) confirmation | Single ELISA or qualitative immunoblot only |
| Diagnostic Sensitivity | 99.9% (ISO-verified dual-method combination) | 92-95% (standalone ELISA) |
| Turnaround Time | Next working day (samples received Mon/Wed by 9 AM) | 3-5 working days |
| Cost | 650 AED (transparent, all-inclusive) | 800-950 AED (variable with hidden add-ons) |
| Regulatory Compliance | DHA/MOHAP Standards, ISO 9001:2015, UAE PDPL | Often minimal external audit verification |
Physician Insight & Safety Protocols
"Anti-GBM antibody testing stands as the definitive serological marker for Goodpasture's syndrome, a rapidly progressive autoimmune emergency where early detection directly influences patient survival. The dual-method ELISA and IFA confirmation protocol practised at DNA Labs UAE provides clinicians with the diagnostic confidence needed to initiate plasmapheresis and immunosuppressive therapy without delay. I strongly advise correlating quantitative antibody titers with renal biopsy histopathology and high-resolution chest imaging for complete clinical assessment."
— Dr. Ajay Singh, General Practitioner, DHA Registration ID: 36234132
Therapy Continuation Advisory
⚠️ Medication Advisory
Maintain all prescribed immunosuppressive, antihypertensive, and respiratory medications as directed by your treating physician. Abrupt cessation of therapy may precipitate clinical deterioration. Consult your specialist before making any medication adjustments.
Patient Safety Exclusion Criteria
Contraindications for Outpatient Sampling
- Active systemic infection or febrile illness within the preceding 48 hours.
- Recent organ transplantation with ongoing immunosuppressive induction therapy.
- Documented hypersensitivity to standard phlebotomy supplies including adhesive dressings.
- Emergency red flags: sudden massive hemoptysis, acute hypoxemic respiratory failure, or oliguric acute kidney injury — proceed directly to the nearest emergency department; do not delay for outpatient blood collection.
Patient FAQ & Clinical Guidance
1. What is the Goodpasture's Syndrome Panel and who requires this test?
This panel detects circulating anti-glomerular basement membrane antibodies that mediate autoimmune injury to renal and pulmonary tissues. It is urgently indicated for individuals presenting with unexplained hematuria, proteinuria, and hemoptysis to confirm anti-GBM disease. A positive result, interpreted alongside clinical and radiographic findings, establishes the diagnosis and directs immediate life-saving intervention including plasmapheresis and immunosuppression.
2. How is the blood sample collected and what is the expected reporting timeline?
A standard venous blood draw of 3 mL serum is performed by our certified mobile phlebotomy team during a scheduled home visit. The specimen is transported to our ISO-accredited laboratory under continuous temperature monitoring. Samples collected by 9 AM on Monday or Wednesday are processed and validated the next working day, enabling rapid clinical decision-making without unnecessary delays.
3. What does a positive anti-GBM antibody result indicate and what are the immediate next steps?
A positive anti-GBM antibody result in the context of renal or pulmonary involvement confirms Goodpasture's syndrome. The immediate clinical pathway includes urgent referral to a nephrologist or pulmonologist, hospital admission, and initiation of plasmapheresis combined with immunosuppressive therapy. Serial anti-GBM antibody titers are subsequently monitored to evaluate treatment efficacy and guide therapeutic duration.
UAE Regulatory & Data Privacy Adherence
This diagnostic service is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All protected health information is encrypted, access-controlled, and processed according to Dubai Health Authority (DHA) and Ministry of Health and Prevention (MOHAP) data privacy standards. Clinical safety protocols and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory operations are ISO 9001:2015 certified under registration INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | Goodpasture's Syndrome Panel (Anti-GBM Antibodies) |
| Price (AED) | 650 |
| Turnaround Time | Next working day (samples received Mon/Wed by 9 AM) |
| Sample Type / Matrix | Serum (3 mL venous blood) |
| Methodology Used | Enzyme Immunoassay (ELISA) with Indirect Immunofluorescence (IFA) confirmation |
| ICD-10-CM Code | M31.0, N08.5* |
| LOINC Code | 43134-6 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
Mobile Phlebotomy Available Daily 8 AM - 11 PM | Results Delivered Next Working Day
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians